GENE THERAPY WITH RECOMBINANT ADENOVIRUS ADKDR-TK AND IL-12 RECOMBINANT RETROVIRUS IN VESSEL TARGETED TREATMENT OF SUBCUTANEOUSLY IMPLANTED HHC IN NUDE MICE

李宝金,邝伟明,朱欠元,赵辉,汪勇,张辉,孙宇
DOI: https://doi.org/10.3969/j.issn.1674-8085.2010.04.021
2010-01-01
Abstract:Objective:To investigate the therapeutic efficacy of Recombinant adenovirus AdKDR-tk and mIL-12 recombinant retrovirus in vessel-targeted treatment of subcutaneously implanted HHC in nude mice.Methods:Thirty-two SCID mice were subcutaneously transplanted with human hepatocellular carcinoma and the tumors were allowed to grow till the volume reached 0.5cm3, then the mice were divided into 4 groups:Ganciclovir group(I), mIL-12 recombinant retrovirus group(II), AdKDR-TK+group GCV(Ⅲ) and AdKDR-TK+mIL-12 recombinant retrovirus+GCV group(IV).Recombinant adenovirus or mIL-12 recombinant retrovirus were injected intra-tumorally in all mice.Ganciclovir(GCV)was given at a dose of 100 mg/(kg·d)(ip)on the following day of injection with recombinant adenovirus for 10 days, Mierovessel density(MVD)of the tumors was determined with the immunohistorchemical methods and the growth of the tumor was observed.Results:Compared with group IV, The tumor inhibitory rate in sroup IV was 62.14 %, The rates in group Ⅲ and group II were 32.73 % and 18.32%(P 0.01).The inhibition rates in group IV were superior to that of group II.The mean MVD in group I, Ⅱ, Ⅲ and IV was 40.1 ± 6.7, 32.2 ± 7.3, 27.6 ± 7.1, and 7.7 ± 4.1(microvessels/mm2), respectively.Conclusion:The results demonstrated that pAdKDR-TK+GCV system efficiently work together in the targeting treatment of vascular endothelial cells of HCC in vivo.And IL-12 could enhance the therapeutic effect.It may be a new treatment approach for human HCC.
What problem does this paper attempt to address?